{
    "clinical_study": {
        "@rank": "75580", 
        "arm_group": [
            {
                "arm_group_label": "ETI-204", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous (IV) single dose"
            }, 
            {
                "arm_group_label": "ETI-204 and IV Ciprofloxacin and Oral Ciprofloxacin", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous (IV) ETI-204 and IV Ciprofloxacin and Oral Ciprofloxacin"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety and tolerability of intravenous (IV) ETI-204 alone and in the presence\n      of IV and oral ciprofloxacin"
        }, 
        "brief_title": "Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and PK of ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Inhalational Anthrax", 
        "condition_browse": {
            "mesh_term": "Anthrax"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Females or males between 18 and 60 years of age\n\n          2. All females, regardless of childbearing potential, must have a negative serum beta\n             human chorionic gonadotropin (\u03b2-hCG) pregnancy test at Screening and Day -1\n\n          3. Females of childbearing potential (i.e., not postmenopausal or surgically sterile)\n             must agree to practice abstinence or to use a medically accepted method of\n             contraception from the time of Screening through 30 days after the final study visit.\n             Acceptable methods of contraception include diaphragm with spermicide; sponge with\n             spermicide; condom with spermicide; or intrauterine device with condom or spermicide.\n             The following contraceptive methods are acceptable only when used with a condom and\n             spermicide: birth control pills, birth control patches, vaginal ring, hormone under\n             the skin, or hormone injections\n\n          4. Postmenopausal females, defined as females who have had amenorrhea for at least 12\n             months either naturally or following cessation of all exogenous hormonal treatments,\n             and have a follicle-stimulating hormone (FSH) level of > 40 mIU/mL at Screening\n\n          5. Females who have undergone surgical sterilization, including hysterectomy, bilateral\n             oophorectomy, bilateral salpingectomy, tubal ligation, or tubal essure \u2265 3 months\n             prior to Screening. Tubal essure requires radiological confirmation of occlusion of\n             the fallopian tubes. Subjects who cannot provide documentation may participate if\n             they agree to follow the methods of contraception specified in Inclusion Criterion #3\n\n          6. Males must agree to practice abstinence or use a condom with spermicide and refrain\n             from sperm donation during the study and for 30 days after the final study visit.\n             Note this does not apply to males who have undergone a vasectomy and can provide\n             documentation of confirmatory sperm count 3 months post procedure.\n\n          7. Provide written informed consent\n\n          8. Willing to comply with study restrictions (see Section 4.5.3 for a complete list of\n             study restrictions)\n\n        Exclusion Criteria:\n\n          1. Pregnant or lactating woman\n\n          2. Clinically-significant comorbidity that would interfere with completion of the study\n             procedures or objectives or compromise the subject's safety\n\n          3. Supine systolic blood pressure (BP) \u2265 150 mmHg or \u2264 90 mmHg or diastolic BP \u2265 95 mmHg\n\n          4. Use of H1 receptor antagonists (i.e. antihistamines) within 5 days prior to Day 1\n\n          5. Evidence of drug or alcohol abuse as determined by the Investigator, within 6 months\n             of Day 1\n\n          6. Positive test result for drugs of abuse (with the exception of medically prescribed\n             drugs) at Screening or on Day -1\n\n          7. Positive test for alcohol at Screening or Day -1\n\n          8. Treatment with an investigational agent within 30 days or five half-lives of the\n             investigational agent at Day 1 (whichever is longer)-\n\n          9. Congenital or acquired immunodeficiency syndrome\n\n         10. Prior solid organ or bone marrow transplant\n\n         11. Positive test for Hepatitis B (surface antigen), Hepatitis C, or human\n             immunodeficiency virus (HIV) at Screening\n\n         12. History of prior treatment for anthrax exposure or prior anthrax infection\n\n         13. Prior immunization with any approved or investigational anthrax vaccine or prior\n             treatment with an investigational anthrax treatment (i.e., ETI-204, raxibacumab, or\n             anthrax immune globulin)\n\n         14. Military personnel deployed in 1990 or after, unless the subject can provide\n             documentation demonstrating they have not previously received any approved or\n             investigational anthrax vaccine\n\n         15. Therapeutic use of systemic steroids, immunosuppressive agents, anticoagulants, or\n             anti-arrhythmics within 1 year prior to Day 1; a single short course (i.e., less than\n             14 days) of systemic steroid therapy is allowed provided it concluded more than 6\n             months prior to Day 1\n\n         16. Donation or loss of > 500 mL of blood within 30 days or plasma within 7 days of Day 1\n\n         17. Prior stroke, epilepsy, relapsing or degenerative CNS disease, or relapsing or\n             degenerative ocular disease\n\n         18. Myocardial infarction or acute coronary syndrome in the past 5 years, active angina\n             pectoris, or heart failure (New York Heart Association scale > I)\n\n         19. History of chronic liver disease\n\n         20. Calculated creatinine clearance (CrCl) of < 30 mL/min using the Cockcroft-Gault\n             equation (see Section 5.1)\n\n         21. Any clinically significant abnormality, in the Investigator's opinion, on\n             electrocardiogram (ECG) or clinical laboratory tests (hematology, clinical chemistry,\n             or urinalysis) at Screening; out of range results may be repeated to confirm\n\n         22. History of allergic or hypersensitivity reactions to other therapeutic antibodies or\n             immunoglobulins\n\n         23. History of any malignant neoplasm within the last 5 years, with the exception of\n             adequately treated localized or in situ non-melanoma carcinoma of the skin (e.g.\n             basal cell carcinoma) or the cervix\n\n         24. Subjects who, in the opinion of the Investigator, are not suitable candidates for\n             enrollment or who may not comply with the requirements of the study\n\n        Exclusion Criteria Specific to the Use of Ciprofloxacin\n\n          1. Hypersensitivity to any fluoroquinolone\n\n          2. At increased risk of Clostridium. difficile (C. difficile) infection (e.g., prior\n             systemic antibiotic therapy or in-hospital stay of greater than 2 nights over the\n             past 6 months, abdominal surgery within 3 months prior to Day 1, a chronic\n             inflammatory bowel disease or prior C. difficile infection)\n\n          3. Any medical condition that may require repeat courses of antibiotics, e.g., recurrent\n             urinary tract or respiratory infections. A short course (i.e.\u2264 10 days) of\n             antibiotics within 6 months prior to Day 1 is not exclusionary.\n\n          4. A history of any tendon rupture\n\n          5. Subjects who smoke or have used tobacco or nicotine containing products within 3\n             months of Day 1.\n\n          6. Use of cation-containing drugs or food supplements within 2 days prior to Day 1\n\n          7. Use of protheophylline, theophylline, methylxanthine, tizanidine, or other drugs\n             metabolized via cytochrome P450 1A (CYP1A) within 30 days prior to Day 1\n\n          8. Use of glyburide, cyclosporine, didanosine, methotrexate, or probenecid and\n             medications that prolong the QT interval within 30 days prior to Day 1 or within 5\n             half-lives of Day 1, whichever is longer\n\n          9. Subjects at high risk for QT prolongation, including:\n\n               1. Baseline prolongation of QTcF \u2265 500 msec\n\n               2. Risk factors for Torsade de Pointes, including hypocalcemia, hypokalemia, sudden\n                  death of unknown cause in a close family member (i.e. biological mother, father\n                  or siblings), a near drowning episode, a family history of either Romano-Ward\n                  syndrome or Jervell and Lange-Nielson syndrome\n\n               3. The use of concomitant medications that prolong the QT interval within 30 days\n                  prior to Day 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01952444", 
            "org_study_id": "AH110"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ETI-204", 
                    "ETI-204 and IV Ciprofloxacin and Oral Ciprofloxacin"
                ], 
                "description": "Intravenous (IV)", 
                "intervention_name": "ETI-204", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "ETI-204", 
                "intervention_name": "IV Ciprofloxacin", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "ETI-204", 
                "intervention_name": "Oral Ciprofloxacin", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ciprofloxacin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66211"
                }, 
                "name": "Quintiles"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of ETI-204 Alone and in the Presence of Ciprofloxacin in Adult Volunteers", 
        "overall_official": [
            {
                "affiliation": "Quintiles", 
                "last_name": "David Mathews, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Davita Clinical Research", 
                "last_name": "Jolene Berg, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety assessments will be assessed by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical assessments, infusion site assessments, and AEs", 
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "71 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01952444"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "All PK parameters will be determined for a single Intravenous (IV) administration of ETI-204, a single IV dose of ciprofloxacin and oral ciprofloxacin at steady state.", 
                "measure": "Pharmacokinetics (PK) analysis", 
                "safety_issue": "No", 
                "time_frame": "71 Days"
            }, 
            {
                "description": "Immunogenicity measured by the percentage of subjects in each study arm with anti-ETI-204 antibody values greater than or equal to cutpoint at Day 1, 9, 43 and 71.", 
                "measure": "Anti-ETI-204 Antibody", 
                "safety_issue": "No", 
                "time_frame": "71 Days"
            }
        ], 
        "source": "Elusys Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elusys Therapeutics", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}